Director

Karen N. Prange

Director·Embecta Corp.

About

Ms. Prange was most recently Executive Vice President and Chief Executive Officer for the Global Animal Health, Medical and Dental Surgical Group at Henry Schein, Inc. and a member of its Executive Committee from 2016 to 2018. In this role, she led a business that generated over $6 billion of revenue across three different business units, growing the business to above-market levels in all business segments. Prior to her role at Henry Schein, she was Senior Vice President of Boston Scientific and President of its Urology and Pelvic Health business and served as General Manager of the Micrus Endovascular and Codman Neurovascular business at Johnson & Johnson Company. Ms. Prange currently serves on the board of AtriCure, Inc. (NASDAQ: ATRC) and WS Audiology A/S.

Since 2022
Tenure 4 yrs

Also at Embecta Corp.

CA Carrie L. Anderson Director RH Robert (Bob) J. Hombach Director DK Devdatt (Dev) Kurdikar President and Chief Executive Officer, Embecta Corp. MP Milton M. Morris, Ph.D. Director CM Claire Pomeroy, M.D. Director (Lead Director effective as of the 2026 Annual Meeting) CR Christopher R. Reidy Director

Past roles

No prior roles disclosed
The proxy statement discloses no roles beyond this person's current position. Disclosure is required only for the most recent five years.

Director compensation

Data from FY 2025
Fees earned or paid in cash
$96,000
Stock awards
$230,004
All other compensation
$2,000
Total
$328,004

Related

Source: Embecta Corp. proxy statement (SEC Schedule 14A)

Where the filing does not disclose a value, this page states "Not disclosed" rather than estimating. Smaller filers are exempt from disclosing metric targets and achievement, and larger filers may omit forward targets for competitive reasons.

See how VectorShift works for your firm

Request Demo